Recent progress in research on drug-induced liver injury (DILI) has been determined by key developments in two areas. First, new technologies allow the identification of genetic risk factors with improved sensitivity, specificity, and efficiency. Second, new mechanistic concepts of DILI emphasize th
Effect of drug pretreatment on CBrCl3-induced liver injury
β Scribed by Mario V. Torrielli; Giancarlo Ugazio; Ludovica Gabriel; Elisa Burdino
- Publisher
- Elsevier Science
- Year
- 1974
- Tongue
- English
- Weight
- 312 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0300-483X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Despite its low incidence, drug-induced liver injury (DILI) continues to have a high impact on the medical community, pharmaceutical industry, and general public. DILI is often difficult to diagnose, and few specific treatments are available. Severe DILI is the primary reason for regulatory actions
New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice. We have examined these
## Abstract Limitations of existing biomarkers to detect liver injury in experimental animals highlight the need for additional tools to predict human toxicity. The utility of cytochrome c (cyt c) as a biomarker in serum and urine was evaluated in two rodent liver injury models. Adult SpragueβDawle
## Abstract Recent studies reported that 3βhydroxyβ3βmethylβglutaryl coenzyme A (HMGβCoA) reductase inhibitors have pleotropic effects independent of their lipidβlowering properties. The present study was undertaken to determine whether treatment with rosuvastatin (RO) would be beneficial in a rat